See more : Takasago International Corporation (4914.T) Income Statement Analysis – Financial Results
Complete financial analysis of Allurion Technologies Inc. (ALUR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Allurion Technologies Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Aimia Inc. (AIM-PA.TO) Income Statement Analysis – Financial Results
- Toyo Sugar Refining Co., Ltd. (2107.T) Income Statement Analysis – Financial Results
- Bounty Oil & Gas NL (BUY.AX) Income Statement Analysis – Financial Results
- Kennede Electronics MFG. Co., Ltd. (002723.SZ) Income Statement Analysis – Financial Results
- PT Bintang Mitra Semestaraya Tbk (BMSR.JK) Income Statement Analysis – Financial Results
Allurion Technologies Inc. (ALUR)
About Allurion Technologies Inc.
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 53.47M | 64.21M | 38.24M | 0.00 |
| Cost of Revenue | 11.97M | 13.49M | 9.05M | 0.00 |
| Gross Profit | 41.50M | 50.73M | 29.19M | 0.00 |
| Gross Profit Ratio | 77.61% | 79.00% | 76.33% | 0.00% |
| Research & Development | 27.69M | 16.97M | 5.73M | 0.00 |
| General & Administrative | 46.02M | 15.37M | 8.82M | 0.00 |
| Selling & Marketing | 46.86M | 50.41M | 27.14M | 0.00 |
| SG&A | 92.88M | 65.77M | 35.96M | 4.56K |
| Other Expenses | 0.00 | -1.15M | -555.00K | -610.00 |
| Operating Expenses | 120.58M | 82.74M | 41.69M | 5.17K |
| Cost & Expenses | 132.55M | 96.22M | 50.74M | 5.17K |
| Interest Income | 0.00 | 10.66M | 49.77K | 0.00 |
| Interest Expense | 10.57M | 4.43M | 3.67M | 0.00 |
| Depreciation & Amortization | 746.00K | 895.00K | 707.00K | 206.30K |
| EBITDA | -69.03M | -32.28M | -12.35M | -5.17K |
| EBITDA Ratio | -129.11% | -48.52% | -32.29% | 0.00% |
| Operating Income | -79.08M | -32.01M | -12.50M | -5.17K |
| Operating Income Ratio | -147.90% | -49.85% | -32.69% | 0.00% |
| Total Other Income/Expenses | -1.27M | -5.59M | 115.00K | 1.00 |
| Income Before Tax | -80.34M | -37.60M | -12.39M | -5.17K |
| Income Before Tax Ratio | -150.27% | -58.56% | -32.39% | 0.00% |
| Income Tax Expense | 264.00K | 143.00K | 3.11M | -206.30K |
| Net Income | -82.30M | -37.74M | -12.39M | -5.17K |
| Net Income Ratio | -153.93% | -58.78% | -32.39% | 0.00% |
| EPS | -2.31 | -1.40 | -0.11 | 0.00 |
| EPS Diluted | -2.31 | -1.40 | -0.11 | 0.00 |
| Weighted Avg Shares Out | 35.58M | 26.92M | 107.81M | 107.81M |
| Weighted Avg Shares Out (Dil) | 35.58M | 26.92M | 107.81M | 107.81M |
Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that the Somerset NHS Foundation Trust (FT) is the first NHS trust in the United Kingdom, and the first non-private sector organisation in...
World first : Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that the Somerset NHS Foundation Trust (FT) is the first NHS trust in the United Kingdom, and the first non-private sector organisation in...
Allurion's Virtual Care Suite Digital Platform Accelerates Commercial Expansion With New Strategic Partnerships
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced further expansion of its Virtual Care Suite (VCS) digital platform with new commercial agreements signed with Lazeo, France's largest aesthetic and weight loss clinic...
Allurion Announces Publication of Randomized, Double-Blind Study Demonstrating Significant Improvement in Obesity-Related Co-Morbidities
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a randomized, double-blind study in Obesity Surgery that demonstrated significant reductions in type 2 diabetes, hypertension, and obstructive sleep apnea...
New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion Program
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced results of research that highlighted the positive impact of the growing interest in anti-obesity medications on Allurion Program awareness and uptake. The global...
Allurion's Digital Platform Gains Traction with Expanded Strategic Partnership
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced an expanded commercial agreement with Weight Doctors®—Germany's leading group of private clinics and centers for weight loss—and the hiring of Brian Conyer to lead...
Allurion Technologies Inc. (ALUR) Q3 2023 Earnings Call Transcript
Allurion Technologies Inc. (NYSE:ALUR ) Q3 2023 Results Conference Call November 13, 2023 8:30 AM ET Company Participants Mike Cavanaugh - ICR of Westwicke Shantanu Gaur - Founder and Chief Executive Officer Chris Geberth - Chief Financial Officer Conference Call...
Allurion to Report Third Quarter 2023 Financial Results on November 13, 2023
NATICK, Mass.--(BUSINESS WIRE)--Allurion to Report Third Quarter 2023 Financial Results on November 13, 2023.
Allurion Completes Enrollment in Pivotal AUDACITY Trial for the Allurion Balloon
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the completion of patient enrollment in its AUDACITY trial. AUDACITY is a randomized, pivotal controlled trial designed to support U.S. Food and Drug Administration (FDA)...
Allurion Featured at the 2023 International Bariatric Club Oxford University World Congress
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced its participation in the 4th International Bariatric Club (IBC) Oxford World Congress, which takes place at Oxford University, September 18-20, 2023. The IBC event, entitled...
Source: https://incomestatements.info
Category: Stock Reports